Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Cross Country Healthcare is a healthcare staffing and workforce solutions provider specializing in travel nursing, allied health professionals, and physician staffing across the United States. The company experienced severe revenue contraction (-33.5% YoY) as pandemic-era premium rates normalized, with operating margins turning negative (-1.3%) as bill rates compressed while SG&A remained elevated. The stock trades at distressed valuations (0.2x P/S, 0.7x P/B) reflecting investor concerns about structural margin compression in a post-COVID staffing environment.
Cross Country operates as a staffing intermediary, recruiting healthcare professionals and placing them with hospitals and healthcare facilities at bill rates that exceed pay rates plus overhead. The company's gross margin (20.4% TTM) represents the spread between what facilities pay and what clinicians receive, covering recruiting costs, benefits, compliance, and profit. Pricing power collapsed post-pandemic as hospital labor shortages normalized, compressing bill rates by an estimated 30-40% from 2022 peaks while clinician pay rates remained sticky downward. The business model requires continuous recruitment to maintain candidate pipelines and relies on healthcare facility demand volatility to justify premium temporary staffing rates over permanent hires.
Travel nurse bill rates and average daily rates - the primary driver of revenue per FTE and gross margin expansion/contraction
Hospital labor shortage intensity - measured by open nursing positions, vacancy rates, and hospital willingness to pay premium rates for temporary staff
Clinician supply dynamics - number of active travel nurses willing to take assignments versus permanent employment
Healthcare facility utilization rates and patient volumes - drives demand for temporary staffing to handle census fluctuations
Regulatory changes affecting nurse-to-patient ratios or staffing requirements at state level
Permanent normalization of travel nurse bill rates to pre-pandemic levels ($1,800-2,200/week versus $3,500+ peaks) as hospitals rebuild permanent staff and reduce reliance on premium temporary labor
Hospital vertical integration into internal float pools and direct hiring of travel nurses, disintermediating staffing agencies and compressing market share
Regulatory risk from potential federal or state legislation capping travel nurse pay rates or requiring staffing agencies to meet minimum wage ratios, compressing gross margins
Technology disruption from direct-to-clinician platforms (Gig-economy models) that bypass traditional staffing agencies with lower take rates
Intense competition from AMN Healthcare (larger scale, $1.5B revenue), Aya Healthcare (private equity-backed), and 100+ regional staffing firms driving bill rate compression
Low switching costs for both clinicians and hospitals - nurses can easily move between agencies, and hospitals can shift vendor relationships based on pricing
Commoditization risk as differentiation erodes in a normalized market - limited ability to command premium pricing without unique specialties or exclusive relationships
Minimal debt risk given 0.01 D/E ratio and $100M+ cash generation capability, but negative ROE (-3.8%) indicates capital is being destroyed at current profitability levels
Working capital pressure if revenue continues declining - accounts receivable may not convert to cash as quickly as payables come due, though 3.45x current ratio provides cushion
Potential goodwill or intangible asset impairment if acquired staffing brands underperform, though not disclosed in available data
moderate - Healthcare staffing demand is partially defensive (hospitals operate through recessions) but highly sensitive to hospital financial health and elective procedure volumes. During economic weakness, hospitals reduce temporary staffing budgets first, cutting premium-priced travel nurses before permanent staff. However, structural nursing shortages provide a floor to demand. The 2023-2025 revenue collapse reflects normalization from pandemic surge rather than pure cyclical weakness, though recession would further pressure hospital staffing budgets.
Low direct sensitivity as the company carries minimal debt (0.01 D/E ratio). Indirect sensitivity exists through hospital system finances - rising rates pressure not-for-profit hospital bond financing costs and reduce endowment returns, tightening operating budgets and reducing willingness to pay premium staffing rates. Higher rates also increase discount rates applied to CCRN's cash flows, compressing valuation multiples, though this is secondary to operational performance.
Moderate - The company extends 60-90 day payment terms to hospital clients, creating meaningful accounts receivable exposure (likely $200-300M based on revenue run rate). Hospital financial distress, particularly among rural and community hospitals facing margin pressure, could increase bad debt expense. However, large health systems represent the core customer base and carry lower credit risk. The 3.45x current ratio suggests adequate liquidity to absorb potential collection issues.
value/contrarian - The stock trades at distressed multiples (0.2x P/S, 0.7x P/B) below tangible book value, attracting deep value investors betting on cyclical recovery or liquidation value. The -54% one-year return and negative margins have driven out growth and momentum investors. High FCF yield (41%) despite negative net income suggests potential for special dividends or buybacks if management believes trough valuation. Not suitable for income investors (no meaningful dividend) or growth investors (structural headwinds). Requires conviction that travel nursing demand will re-accelerate or that cost cuts can restore mid-single-digit margins.
high - Healthcare staffing stocks exhibit extreme volatility tied to hospital labor market conditions. The stock's -54% annual return and -37.9% six-month return demonstrate high beta to healthcare labor trends. Small market cap ($300M) amplifies volatility through limited float and institutional ownership changes. Quarterly earnings likely show significant beats/misses based on bill rate fluctuations of 5-10%, driving 15-25% single-day moves. Estimated beta of 1.5-2.0x relative to healthcare sector.
